Clinical Trials Logo

Leukemia, Myeloid, Chronic clinical trials

View clinical trials related to Leukemia, Myeloid, Chronic.

Filter by:

NCT ID: NCT00732186 Withdrawn - Clinical trials for Leukemia, Myeloid, Chronic

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML

NCT ID: NCT00539656 Terminated - Clinical trials for Acute Myeloid Leukemia

Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers

Cord Blood
Start date: December 20, 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to evaluate the safety of transplantation of two cord blood products, including toxicities in patients following high-dose, myeloablative chemotherapy for blood malignancies. It is also to determine if the use of two cord products results in an improvement in neutrophil engraftment.

NCT ID: NCT00538447 Active, not recruiting - Clinical trials for Leukemia, Myeloid, Chronic

Prospective Database for Chronic Myelogenous Leukemia

Start date: June 2007
Phase: N/A
Study type: Interventional

Prospective Database for Chronic Myelogenous Leukemia

NCT ID: NCT00538109 Completed - Clinical trials for Leukemia, Myeloid, Chronic

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Start date: October 2007
Phase: N/A
Study type: Interventional

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

NCT ID: NCT00455221 Completed - Clinical trials for Leukemia, Myeloid, Chronic

Safety Assessment of a Multipeptide-gene Vaccine in CML

Start date: February 2008
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety of a peptide-gene vaccine against CML in patients under Imatinib treatment. We will also perform some laboratory tests suggesting biological response.

NCT ID: NCT00449761 Terminated - Clinical trials for Leukemia, Myeloid, Chronic

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Start date: February 23, 2007
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic myeloid leukemia who are in accelerated phase or blast phase (blast crisis) with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors

NCT ID: NCT00406393 Completed - Clinical trials for Myelodysplastic Syndromes

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

Start date: November 2006
Phase: Phase 3
Study type: Interventional

The study is designed as a phase III, randomized, open label, multicenter, prospective, comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis after human leukocyte antigen (HLA)-matched, related, peripheral blood stem cell transplantation in individuals with hematologic cancer. Participants will be stratified by transplant center and will be randomly assigned to the sirolimus/tacrolimus or tacrolimus/methotrexate arms at a 1:1 ratio.

NCT ID: NCT00393380 Terminated - Lymphoma Clinical Trials

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

Start date: September 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the addition of parathyroid hormone after a sequential cord blood transplant will improve engraftment, which is the ability of the transplanted stem cells to grow and to successfully begin producing new blood cells.

NCT ID: NCT00320190 Terminated - Clinical trials for Leukemia, Myeloid, Chronic

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy of dasatinib with that of high-dose (800-mg) imatinib in participants with chronic phase chronic myeloid leukemia who achieved only a suboptimal response after at least 3 months of monotherapy with 400-mg imatinib. The safety of these treatments will also be evaluated.

NCT ID: NCT00306332 Terminated - Lymphoma Clinical Trials

T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation

Start date: March 2006
Phase: Phase 3
Study type: Interventional

T-cell and B-cell depletion in allogeneic peripheral blood stem cell transplantation by using immunomagnetic negative and positive selection procedures Background: Removal of T-cells from the donor graft (T-cell depletion) offers the possibility for prevention of GVHD and subsequently less transplant related morbidity and mortality after allogeneic stem cell transplantation (SCT). There are several techniques to deplete T-cells from the stem cell grafts e.g. physical, immunological and combined physical / immunological separation methods. All these techniques result in a stem cell graft with sufficient CD34+ stem cells combined with an adequate depletion of T and B cells. CD34+ selected stem cell grafts are very pure and do not contain any additional cell populations. In contrast, CD3+/CD19+ depleted grafts still contain NK-cells, monocytes and dendritic cells that are part of the innate immune system. Theoretically,the presence of these cells may positively influence immunological reconstitution and the graft-versus-leukaemia (GVL) effect, respectively, resulting in improved outcome after SCT Objectives: To evaluate the differences in immunological reconstitution, transplant related mortality, disease-free survival and overall survival after T-cell depleted allogeneic SCT for haematological malignancies using either immunomagnetic CD34+ selection or immunomagnetic CD3+/CD19+ depletion using the CliniMACS system in approximately 270 consecutive patients. Additionally in this study in 20 consecutive patients the kinetics of NK-cel reconstitution and differences in NK-cell repertoire will be monitored. NK-cell mediated anti-tumor reactivity will be monitored in patients transplanted with and without NK-cells in the stem cell graft (CD3+/CD19+ depletion, versus CD34+ selection). Secondary objectives are to evaluate the clinical relevance of minor histocompatibility-specific cytotoxic T-cell responses for the GVL effect, the kinetics of NK-cell reconstitution and differences in NK-cell repertoire using the different T-cell depletion protocols. Design: Single center prospective randomised phase III study Population: Patients eligible for allogeneic SCT according to the standard criteria of our institution who will receive an allogeneic T- and B-cell depleted SCT with peripheral stem cells of an HLA-identical sibling donor or an HLA-identical unrelated voluntary (VUD) donor. Intervention: T-cell depletion will be conducted using two different techniques: either immunomagnetic CD34+ selection or immunomagnetic CD3+/CD19+ depletion. Endpoints: Primary endpoints are immunological reconstitution, relapse, disease free survival and overall survival. Secondary endpoints: NK-cell reconstitution and NK-cell mediated anti-tumour reactivity. Cytotoxic T-cell responses for the GVL effect. Estimated efforts and risks for participating patients: We don't expect any extra patient efforts or risks because T-cell depletion is a standard procedure in our clinic for many years. There is extensive experience with immunological T-cell depletion techniques. We hypothesize CD3+/CD19+ depletion will favour stem cell transplant outcome. Immunological and molecular biological studies will be performed on blood samples already obtained as part of the standard protocol.